Evidence map›Paper›PMID 38433831›Full record

ArticleFrontiers in immunology2024

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.

Nisha D Almeida, Ian Schiller, Danbing Ke, Elsa Sakr, Maria Plesa, Sandeep Vanamala, Anne-Laure Moneger, Maria Bazan, Chiara Lucchesi, Natalia Wozniak and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. BMJ open · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Nisha D AlmeidaDepartment of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Ian SchillerHealth Technology Assessment Unit, McGill University Health Centre, Montreal, QC, Canada.
Danbing KeTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Elsa SakrTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Maria PlesaTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Sandeep VanamalaTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Anne-Laure MonegerTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Maria BazanTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Chiara LucchesiTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Natalia WozniakTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
Jorg H FritzGoodman Cancer Centre, and Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
Ciriaco A PiccirilloInfectious Diseases and Immunology in Global Health Program, Research Institute of Research Institute of the McGill University Health Center, and Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
Martin PelchatFaculty of Medicine, Department of Biochemistry, Microbiology and Immunology and University of Ottawa, Ottawa, ON, Canada.
Corey ArnoldFaculty of Medicine, Department of Biochemistry, Microbiology and Immunology and University of Ottawa, Ottawa, ON, Canada.
Yannick GalipeauFaculty of Medicine, Department of Biochemistry, Microbiology and Immunology and University of Ottawa, Ottawa, ON, Canada.
Pauline S McCluskieFaculty of Medicine, Department of Biochemistry, Microbiology and Immunology and University of Ottawa, Ottawa, ON, Canada.
Marc-Andre LangloisFaculty of Medicine, Department of Biochemistry, Microbiology and Immunology and University of Ottawa, Ottawa, ON, Canada.
Kaberi DasguptaDepartment of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Bruce D MazerTranslational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
McGill University Health Centre · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vaccination against COVID-19 is highly effective in preventing severe disease and hospitalization, but primary COVID mRNA vaccination schedules often differed from those recommended by the manufacturers due to supply chain issues. We investigated the impact of delaying the second dose on antibody responses to COVID mRNA-vaccines in a prospective cohort of health-care workers in Quebec. Methods: We recruited participants from the McGill University Health Centre who provided serum or participant-collected dried blood samples (DBS) at 28-days, 3 months, and 6 months post-second dose and at 28-days after a third dose. IgG antibodies to SARS-CoV2 spike (S), the receptor-binding domain (RBD), nucleocapsid (N) and neutralizing antibodies to the ancestral strain were assessed by enzyme-linked immunosorbent assay (ELISA). We examined associations between long (≤89 days) versus short (<89 days) between-dose intervals and antibody response through multivariable mixed-effects models adjusted for age, sex, prior covid infection status, time since vaccine dose, and assay batch. Findings: The cohort included 328 participants who received up to three vaccine doses (>80% Pfizer-BioNTech). Weighted averages of the serum (n=744) and DBS (n=216) cohort results from the multivariable models showed that IgG anti-S was 31% higher (95% CI: 12% to 53%) and IgG anti-RBD was 37% higher (95% CI: 14% to 65%) in the long Interpretation: Our study indicates that extending the covid primary series between-dose interval beyond 89 days (approximately 3 months) provides stronger antibody responses than intervals less than 89 days. Our demonstration of a more robust antibody response with a longer between dose interval is reassuring as logistical and supply challenges are navigated in low-resource settings.

Indexed as

Antibody FormationCOVID-19Antibodies, NeutralizingCOVID-19 VaccinesHumansImmunoglobulin GProspective StudiesRNA, MessengerRNA, ViralSARS-CoV-2Antibodies, NeutralizingCOVID-19 VaccinesImmunoglobulin GRNA, MessengerRNA, Viraladaptive immunityCOVID-19humoral immunityIgGmRNA vaccinationneutralizing antibodies (NAB)vaccine responsevaccine schedule

Identifiers

PMID38433831
PMCPMC10904688
OpenAlexW4391880524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.